Oral Liushen pill for patients with COVID-19: A prospective randomized controlled trial.

"CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest."

"We thank all participants for their contributions to the study. This study was supported and funded by the Jiangsu Provincial Administration of Traditional Chinese Medicine emergency Research Project on COVID‐19 Prevention and Treatment (JSZYJ202201). Funding played no role in the study design, collection, management, or analysis, nor in the interpretation of the data, writing of the report, or decision to submit the report for publication."

"Between April 10 and May 2, 2022, a total of 181 patients with asymptomatic infection and mild Omicron BA.2 were randomly assigned to the trial (n = 91) or control (n = 90) groups. All the patients completed their treatment. This study was registered in the China Clinical Trials Registration Center (ChiCTR2200058859)."